Caplin Point Laboratories is currently trading at Rs. 560.20, up by 24.95 points or 4.66% from its previous closing of Rs. 535.25 on the BSE.
The scrip opened at Rs. 534.85 and has touched a high and low of Rs. 574.00 and Rs. 525.85 respectively. So far 108077 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 574.00 on 18-May-2017 and a 52 week low of Rs. 188.00 on 13-Jun-2016.
Last one week high and low of the scrip stood at Rs. 574.00 and Rs. 441.50 respectively. The current market cap of the company is Rs. 4275.38 crore.
The promoters holding in the company stood at 69.06%, while Institutions and Non-Institutions held 5.65% and 25.29% respectively.
Caplin Point Laboratories has received the Establishment Inspection Report (EIR) from USFDA for the inspection carried out during October 21 - 27, 2016 at its sterile injectable plant at Gummidipoondi, Tamil Nadu. The facility, capable of manufacturing Liquid Injectables in Vials, Ampoules, Lyophilized Vials and Ophthalmic dosages, is also approved by EU-GMP and ANVISA-Brazil.
Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.
